Opinion|Videos|November 26, 2025

Key Objectives and Data from ASCENT-04

This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.

The ASCENT-04/KN-D19 study evaluated the efficacy of sacituzumab govitecan (SG) combined with pembrolizumab versus standard chemotherapy plus pembrolizumab in first-line treatment of metastatic TNBC. The study addressed a critical unmet need: improving outcomes in a population with historically limited options. SG has demonstrated benefit in the second-line setting, and combining it with immunotherapy upfront aimed to enhance clinical responses.


Latest CME